Overview

• The £50 million (~$67 million) Series B was led by the Dementia Discovery Fund and included the British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, and Brandon Capital.
• Lead candidate NRG5051 is an oral small molecule reported to bind a specific protein the company dubs ‘protein A’ and to cross the blood–brain barrier.
• Company statements indicate first‑in‑human testing could begin as early as December 2025 in one report, with other coverage citing an early 2026 start.
• NRG plans parallel early studies in ALS/MND and Parkinson’s to seek clinical proof‑of‑concept for its mPTP‑targeting approach.
• The firm is developing a PET‑labeled version of its drug and aims to validate a biomarker during early trials, with backup compounds progressing in the pipeline.